The Acromegaly Consensus Group considered many of the advances that have occurred in the management of acromegaly over the past 10 years. First, the growth hormone receptor antagonist pegvisomant ...

Affected populations: Acromegaly is estimated to affect approximately 50 to 70 people out of every million. However, the true ...

Acromegaly is due to hypersecretion of growth hormone and insulin-like growth factor I (IGF-I). The aim of treatment is to limit this excess secretion and to reduce morbidity and mortality.

George Moanaroa believes the spiritual world of Te Ao Māori and the medical world joined forces to save his life. Moanaroa ...

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the ...

A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release. Adults diagnosed with endogenous Cushing’s syndrome have a higher ...

AIP (Aryl Hydrocarbon Receptor Interacting Protein) is the name of the gene which causes pituitary adenomas in some families with acromegaly and occasionally prolactinomas, and very rarely with other ...